Daniele Vallisa
Overview
Explore the profile of Daniele Vallisa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ragaini S, Galli A, Genuardi E, Gandossini M, Alessandria B, Civita A, et al.
Blood Adv
. 2025 Jan;
PMID: 39808795
Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear. Here, we report a comprehensive NGS-based analysis...
2.
Arcari A, Morello L, Borotti E, Ronda E, Rossi A, Vallisa D
Cancers (Basel)
. 2024 Oct;
16(20).
PMID: 39456577
Chronic Lymphocytic Leukemia (CLL) is the most frequent type of leukemia in Western countries. In recent years, there have been important advances in the knowledge of molecular alterations that underlie...
3.
Sportoletti P, Laurenti L, Chiarenza A, Gaidano G, Albi E, Mauro F, et al.
Hematol Oncol
. 2023 Sep;
42(1):e3216.
PMID: 37772620
Chronic lymphocytic leukemia (CLL) therapies differ in efficacy, side effects, route, frequency, and duration of administration. We assessed patient preferences for treatment attributes and evaluated associations with disease stage, treatment...
4.
Efficace F, Al Essa W, Platzbecker U, Niscola P, Palumbo G, Caocci G, et al.
Hemasphere
. 2023 Sep;
7(9):e944.
PMID: 37663671
Health-related quality of life (HRQoL) is an important goal of therapy for patients with myelodysplastic syndromes (MDS); however, little is known about HRQoL of these patients at clinical presentation. We...
5.
Arcari A, Cavallo F, Puccini B, Vallisa D
Front Oncol
. 2023 Jul;
13:1214026.
PMID: 37465115
Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (>65 years of age) and this population is expected to increase in the following years. A simplified geriatric assessment based...
6.
Arcari A, Rigacci L, Tucci A, Puccini B, Usai S, Cavallo F, et al.
Blood Adv
. 2023 Jun;
7(15):4160-4169.
PMID: 37276080
Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially...
7.
Arcari A, Tabanelli V, Merli F, Marcheselli L, Merli M, Balzarotti M, et al.
Br J Haematol
. 2023 Feb;
201(4):653-662.
PMID: 36733229
Up to 10%-15% of diffuse large B-cell lymphoma (DLBCL) are related to hepatitis C virus (HCV) infection, in particular in elderly patients. The Fondazione Italiana Linfomi has recently published a...
8.
Tiacci E, Mancini A, Marchetti M, DElia G, Candoni A, Morotti A, et al.
Br J Haematol
. 2022 Dec;
201(3):411-416.
PMID: 36541031
Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we...
9.
Barr P, Tedeschi A, Wierda W, Allan J, Ghia P, Vallisa D, et al.
Clin Cancer Res
. 2022 Aug;
28(20):4385-4391.
PMID: 35939599
Purpose: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and...
10.
Merli M, Rattotti S, Spina M, Re F, Motta M, Piazza F, et al.
J Clin Oncol
. 2022 Jun;
40(35):4060-4070.
PMID: 35714311
Purpose: We prospectively treated patients with hepatitis C virus (HCV)-associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in...